Manhattan Associates Wins Google Cloud Business Applications Partner of the Year Award for Supply Chain and Logistics
24.4.2025 10:00:00 EEST | Business Wire | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced that it has received the 2025 Google Cloud Business Applications Partner of the Year Award for Supply Chain and Logistics. This prestigious award highlights Manhattan’s role as an innovator within the Google Cloud ecosystem, its commitment to driving customer success, and its pioneering application of Agentic AI and Generative AI (GenAI) within the Manhattan Active® Suite over the past year.
“Google Cloud’s Partner Awards recognize partners who have created outsized value for customers through the delivery of innovative solutions and a high level of expertise,” said Kevin Ichhpurani, President, Global Partner Ecosystem, Google Cloud. "We're proud to announce Manhattan Associates as a 2025 Google Cloud Partner Award winner and celebrate their impact enabling customer success over the past year."
“We are honored to be recognized as Google Cloud’s 2025 Business Applications Partner of the Year Award for Supply Chain and Logistics,” said Sanjeev Siotia, executive vice president and CTO, Manhattan Associates. “This award is a testament to the deep collaboration between Manhattan and Google Cloud, as we work together to bring cutting-edge cloud infrastructure, data analytics, Agentic AI and GenAI capabilities to our joint customers. We look forward to continuing this partnership and driving the future of resilient, AI-driven supply chains and omnichannel commerce.”
At the core of Manhattan’s AI-powered innovations is Manhattan Active® Assist; an intelligent, contextual GenAI assistant designed to transform how users interact with the Manhattan Active solutions. Included with all Manhattan Active subscriptions, Manhattan Assist provides a natural language summary of how applications are currently configured and gives instant, accurate responses to questions about product functionality, API structures and more, across multiple personas, roles, and functions.
Manhattan Active® Maven is the company’s Agentic AI offering – an AI powered agent infused with order, payment, store location, and product availability information to deliver personalized, contextual customer service, akin to those delivered by human agents. Built on an Agentic AI platform and Google Gemini models, Manhattan Active Maven is easy to implement and embeds seamlessly with websites and mobile applications, deflecting customer service inquiries, while boosting customer satisfaction and loyalty.
“Manhattan Active Assist and Manhattan Active Maven showcase the real-world power of AI in supply chain and logistics, driving unprecedented levels of personalization, productivity, and cost-savings. Manhattan’s continued partnership with Google Cloud enables us to deliver scalable, resilient and innovative solutions that address the complex challenges of modern supply chain networks,” Siotia finished.
Recently, Manhattan and Google Cloud collaborated on the second edition of the Unified Commerce Benchmark—the industry's only analysis of unified commerce in specialty retail based on real-world purchases, returns, and customer interactions across digital and physical channels. The 2025 edition revealed the common attributes of the most successful retailers, tangible retail best practices, and key opportunities to enhance customer value through modernized operations.
Receive up-to-date partner news directly from Manhattan Associates here.
ABOUT MANHATTAN ASSOCIATES
Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.
Manhattan Associates designs, builds, and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment centre, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424833809/en/
Contacts
Press Contact:
James Canham-Ash
Manhattan Associates
jash@manh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom